Melanoma News & Features
Antioxidants may double the rate of metastasis in malignant melanoma.
Current results from a clinical trial comparing a combination of two targeted therapies with a single-agent treatment for advanced melanoma has shown patients are living significantly longer with the combination therapy.
Skin self-examination (SSE) training to aid early detection of melanoma recurrence is beneficial for patients with melanoma and their partners, and has additional benefits for those who report having low relationship quality because it gives them activities to do together.
Online targeted advertising based on Google search terms may be an effective way to deliver targeted skin cancer prevention education.
Accelerated approval for nivolumab and ipilimumab for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.
- Gay, Bisexual Men Report Higher Rates of Skin Cancer Than Heterosexual Men
- Clinical Trial Demonstrates Superior Results With Immunotherapy vs Chemotherapy for Lung Cancer
- Half-Match Donors May be the Perfect Match In Transplantation for Blood Cancers
- Initial Safety Report Finds Acceptable Safety With Ibrutinib for Asymptomatic, High-Risk CLL
- Older Patients with Hodgkin Lymphoma Benefit from Treatment with Brentuximab Vedotin
- Tumor Grade (Fact Sheet)
- Harms of Cigarette Smoking and Health Benefits of Quitting (Fact Sheet)
- Two-Drug Combination Shows Promise Against One Type of Pancreatic Cancer
- Clinical Trial Shows Vaccine Clears Some Precancerous Cervical Lesions
- Nutrition counseling recommended to reduce malnutrition in oncology patients
- Investigational Therapy Efficiently Depletes Immune System-Suppressing Treg Cells
- Handling closed system device-incompatible chemotherapy agents
- Detecting Cancer While It Is Still Small Impacts Survival
- Antioxidants May Be Harmful in Patients With Melanoma
- Gene Therapy Doubles Survival in Recurrent Glioblastoma
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|